Q32 Bio Inc. (QTTB)

Pharmaceutical Preparations · market cap $298M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Q32 Bio Inc. (QTTB) is a small-cap pharmaceutical company with a market cap of ~$190M and ~$50.8M in cash, developing bempikibart (ADX-914) in Phase 2 for Alopecia Areata and Atopic Dermatitis. A Phase 2 completion was logged on 2026-06-15, with a data readout catalyst imminent on 2026-07-13 — making this a binary, near-term event. The company carries elevated dilution risk and a 24-month cash runway.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
bempikibart (ADX-914)	Phase 2	Alopecia Areata
ADX-914	Phase 2	Atopic Dermatitis

Price & technical context

3-month

-37.0%

6-month

+35.0%

12-month

+316.7%

52-wk range

$1.93–$21.38

vs 50-day MA

-38.7%

vs 200-day MA

-5.2%

Realized vol

144.9%

Max drawdown

-97.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for QTTB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.